Compare Lockheed Martin Corporation (LMT) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lockheed Martin Corporation vs Novavax Inc — how do they compare? Lockheed Martin Corporation trades at $509.59 (market cap $117.22B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: Lockheed Martin Corporation is far larger — about 64.4× Novavax Inc's market cap, and Lockheed Martin Corporation pays a 2.72% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lockheed Martin Corporation for 86 Days and Novavax Inc for 59 Days on average.
| LMT | NVAX | |
|---|---|---|
Market Cap | $117.22B | $1.82B |
Volume | 1,101,121 | 6,198,505 |
Sector | Industrials | Health |
52-Week High | $676.70 | $12.75 |
52-Week Low | $439.19 | $6.22 |
Typical Hold Time | 86 Days | 59 Days |
Enterprise Value | $133.96B | $1.39B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lockheed Martin (LMT) trades at $507.89, up 1.74% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported Q2 2026 EPS beat but missed Q1 and Q4 2025 expectations, with revenue growth from $75.05B in 2025 to projected $77.0B in 2026. Recent news highlights AI integration and F-35 program developments, while analyst consensus remains strongly bullish with a $635.33 price target.
LMT offers stable defense sector exposure with 23 consecutive dividend increases and strong cash flow, but faces execution risks on fixed-price contracts and competitive pressures. The stock trades at reasonable valuations (P/E 18.73, P/S 1.53) with high institutional support, though technical weakness near support at $503 requires monitoring for sustained upward momentum.
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and a strong buy consensus from analysts (73.9% buy ratings). The company reported a net income of $440.3M in 2025, a significant turnaround from prior losses, though 2026 projections show a return to negative margins. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: near-term catalysts include partnership-driven growth and vaccine approvals, but persistent cash burn and projected 2026 losses pose risks. Investor sentiment is buoyed by recent earnings beats and strategic shifts, yet execution on profitability remains critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
